

Interpreting the immunohistological mechanisms underpinning pelvic mesh rejection: a systematic review of existing literature

Dr Claire Mecklem (Royal Darwin Hospital), A/Prof Kylie Mansfield (University of Wollongong), Dr Zhouren Chen (Prince of Wales Hospital)

Introduction

Pelvic mesh rejection is a recognized complication faced by women undergoing surgical treatment for pelvic organ prolapse (POP); a condition where pelvic organs descend into the vagina secondary to weakened pelvic floor ligaments and musculature (Royal Australian and New Zealand College of Obstetricians and Gynaecologists, 2021). The objective of this systematic literature review was to investigate the immunohistological response to inserted pelvic mesh and identify the underlying processes contributing to inflammation at the site of mesh insertion and subsequent complications.

Aims & Methods

The aim of this systematic literature review is to characterise the immunological mechanisms underpinning pelvic mesh rejection. PubMed, Scopus, Web of Science and Cochrane databases were searched between September and November 2023, with results refined to include females aged 18-64. Search strings included “pelvic” and “mesh” or “graft” and “gynae*” and “mesh” or “graft” and “transvaginal” and “mesh” or “graft” and “transabdominal” and “mesh” or “graft” and “synthetic” and “mesh” or “graft” and “biomaterial*” or “tissue engineering” or “native tissue”. Topic and abstract terms included “pelvic organ prolapse surgery” or “prolapse repair” or “urogenital repair” or “pelvic floor repair”. Key words included “inflammation” or “rejection” or “complication” or “foreign body response” or “foreign body reaction” or “FBR” or “histopathology” or “immunohistochemistry” or “immun*”. A total of 175 papers were screened by title and abstract, with a total of 13 studies selected for inclusion: 6 human studies and 7 animal studies. Image 1 reflects how studies were included or excluded from this systematic literature review.





Image 1: PRISMA diagram



Results

Review data reflected three key, recurrent themes: cytokine expression, inflammatory cell infiltration and tissue remodelling. It is hypothesized that these combined responses amalgamate to a foreign-body reaction triggered by insertion of polypropylene mesh, leading to inflammation, wound healing and fibrous encapsulation that contributes to host-mesh rejection. Several studies have analysed explanted mesh, identifying macrophages, neutrophils and mast cells that are well-established in acute and chronic inflammation (Dievernich et al., 2022). Various human studies (Nolfi et al, 2016; Artsen et al, 2020) have found increased expression of pro-inflammatory cytokines: including TNF- α , which is responsible for immune cell recruitment in damaged tissue and TGF- β , a potent immune regulator, which had increased expression in extracted mesh compared with adjacent vaginal wall tissue. Both these findings were similarly found in animal studies (Brown et al, 2015; Dias et al, 2016; Ai et al, 2020).

Several studies (Dias et al., Wang et al.) reported on specific aspects of the remodelling phase of the inflammatory response following mesh insertion. Authors theorised that mesh complications (ie mesh extrusion or pain) may be due to capsular overgrowth and unresolved inflammation in situ; with both studies citing increased MMP expression leading to collagen break down and fibrous exposure. This is important as in human studies majority of indications for mesh extraction were due to development of pain (secondary to mesh) or mesh exposure. Cellular inflammatory responses were consistently observed across human and animal studies following pelvic mesh implantation. Elmer et al demonstrated significantly increased macrophage and mast cell infiltration in human vaginal tissue 12 months after mesh implantation, supporting the presence of a persistent chronic inflammatory response. Wang et al (2023) reported strong correlations between macrophage (CD68/CD163) and neutrophil (CD15) expression, with the highest neutrophil counts observed in severely degraded mesh. Increased adaptive immune cell infiltration was also identified, with Wang et al (2023) also demonstrating an association between T-cell activation (CD86) and neutrophil expression, while Eisenach et al (2021) reported increased B-lymphocyte, plasma cell, fibroblast and lymphocyte expression in vaginal tissue 12 months following mesh insertion. Following mesh explantation for pain or exposure, Tennyson et al (2019) observed increased helper, regulatory and cytotoxic T-cell populations compared with controls. Artsen et al (2019) found regulatory T-cell density was inversely associated with fibrosis, suggesting altered immune regulation may contribute to pathological tissue remodelling. Consistent with these findings, Brown et al (2015) demonstrated dense peri-fibre inflammatory infiltrates in a primate model, composed predominantly of leukocytes, including macrophages, T cells, B cells and mast cells. Collectively, these findings indicate that pelvic mesh implantation is associated with persistent innate and adaptive immune cell activation and chronic inflammation.



Discussion

The mechanisms behind the inflammatory response leading to mesh rejection are complex and challenging to unravel. In human studies, the primary indications for mesh removal were pain (reported in 4 of 6 studies) and mesh exposure (also reported in 4 of 6 studies). Most pelvic mesh removed due to complications exhibits physical deformities, with mesh shrinkage, contraction, or retraction being more prevalent in women experiencing pain (Svabik et al., 2011; Rogowski et al., 2013). Although the mechanism behind pain generation remains unclear, the results of this review suggest it may arise from chronic inflammation leading to tissue remodelling with fibrotic encapsulation resulting from a persistent foreign body response (Image 2). The mesh triggers an inflammatory response, initially recruiting pro-inflammatory cytokines and activating matrix metalloproteinases (MMPs) that degrade the surrounding extracellular matrix (ECM). Tissue damage leads to tissue infiltration with inflammatory cells including macrophages, mast cells and neutrophils. Over time this then activates the acquired immune response. T cells and B cells then initiate collagen deposition hereby encapsulating the mesh to further protect the host. Mesh then gradually shrinks, exerting tension on surrounding tissues (such as the vaginal wall) and leading to pain. This hypothesis is supported by findings of Velemir et al., 2010 and Eisenberg et al., 2014, who describe removed pelvic mesh shrinkage exceeding 50% of the size originally inserted. On the other hand, mesh exposure may be precipitated by increased tissue breakdown secondary to increased MMP expression, as reflected in the study by Nolfi et al (2016). In usual healing scenarios, inflammatory cells and wound cells are triggered to release MMPs, which subsequently break down the ECM. However, when pelvic mesh is introduced, increased expression of MMPs is seen, that can then be followed with pro-inflammatory macrophage infiltration and subsequent tissue breakdown.

Strengths & Limitations

A significant limitation identified with this review was the discrepant duration between human studies (1-44 months) and animal studies (3 months). In human studies there was also a lack of “true control” group as mesh is seldom removed in those who do not experience complications. However, majority of studies did include a control group, be it autologous or matched control, which also improved result validity; adding strength to comments made about general findings. Moreover, as the study design is a systematic literature review, all included literature has been rigorously peer reviewed; increasing the credibility of claims and reliability of synthesized findings.

Conclusion & Implications for Clinical Practice

The precise mechanism underlying pelvic mesh rejection remains unclear despite multiple studies analysing the foreign body response to mesh at a cellular level. Findings from the included reviews suggest fibrous encapsulation as a host-protective mechanism possibly responsible for pain. Alternatively, mesh exposure may be characterized by increased matrix metalloproteinase (MMP) expression, leading to tissue degradation. The lack of suitable alternatives to pelvic mesh remains met with restriction via the Therapeutic Goods Administration; prohibiting its use for surgical repair of pelvic organ prolapse within Australia. This is in spite of the low levels of pelvic mesh rejection identified by articles included in this review as well as larger reviews such as PROSPECT (2017) and Reid et al (2023). Should a feasible alternative mesh be created, it is imperative that longitudinal population studies be undertaken prior to the product becoming commercially available so as to avoid the numerous complications that pelvic mesh initially created for some patients.

Image 2: Foreign Body Response. Taken from Abhari et al., 2021

